A peptide catalog priced in the open, a semaglutide headline that is a first-month price, and a same-price claim above a card that steps up.
- Semaglutide$199/mo intro
- Tirzepatide$299/mo
Assume we may earn a commission, at no cost to you. Partners we work with carry a small, fixed edge in where they are listed; the scores themselves are not adjusted.
- Semaglutide
- $199/mo (the advertised figure is a first-month rate, compounded)
- Tirzepatide
- $299/mo
- Coverage
- All 50 states
- Brand-name
- Compounded only
The scorecard
Longevixx scored on our six published factors. See the methodology.
What we like
- Nineteen peptide programs are priced publicly on their own page, which is far more disclosure than the GLP-1 line carries
- Tirzepatide is priced at a single standing rate with no introductory discount to step off
- An oral and a microdose program sit alongside the standard injection
- A phone number, an email address and clinical hours are all published
- Auto-refill is switched off from the patient portal, and a notification lands five to seven days before each charge
The caveats
- The semaglutide headline is a first-month price; the standing rate is higher, and the homepage prints the discounted figure as a floor
- A same-price, all-dosages, everything-included claim sits directly above a card whose price rises after month one
- Two patient counts and three different average ratings are published across the site and the funnel, none of them attributed to any review platform
- The homepage says telehealth in 50 states while the contact page says the states where it is licensed and the FAQ says the states where it is available; no list exists
- Neither the microdose nor the oral program ever names its molecule, no pharmacy is named, the compounding class appears nowhere, and no clinician, medical group or NPI is published
The verdict
Best for: A tirzepatide buyer, or a peptide shopper — the semaglutide headline is not the semaglutide rate.
Ranked #287 of 548 providers we have reviewed — for comparison, read what CoreAge Rx scores, and why, ranked #1. In the ranking it sits between FMmeds at #286, 64/100 above and MEDVi at #288, 64/100 below, with the ElixaMD write-up the next one down.
Weighing it against something else? Every provider we would put in front of Longevixx is ranked on price honesty, prescriber access and cancellation terms. For the wider picture, every review we have published ranks the field on the same six factors. We have also compared it head to head: CoreAge Rx vs Longevixx goes to CoreAge Rx, 94/100 to 64/100.
Compare Longevixx
Compare with other providers
The closest reviews to Longevixx by Verdict Score — the realistic shortlist if you are weighing this one up.
- #307Vital Edge— Vital Edge is a Chattanooga, TN telehealth practice offering physician-supervised GLP-1 weight loss nationwide by video, with medication shipped to your door each month.64/100
- #308Youth & Soul— Ten-vertical telehealth marketplace selling compounded GLP-1 tiers alongside HRT, ED, nootropics and peptides, running on the Bask Health platform.64/100
- #309Aquivia Health— Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…64/100
- #310Lttl— Compounded semaglutide and tirzepatide injections plus a microdose line, with every commitment length priced on one public page and one flat price at every dose.61/100
- #311MyStart Health— A fast-onboarding compounded GLP-1 service with a genuine dose price-lock, undermined by quiz-gated pricing and unnamed pharmacies.63/100
- #312Fresh Day Meds— Compounded semaglutide and tirzepatide sold on plan tiles that print the dose and renewal term, though the advertised $99 headline is a starter-dose, three-month prepaid rate.63/100
Pricing, states and verification reflect Longevixx's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on Longevixx's site. Not medical advice; see our disclosure.